{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:11:12Z","timestamp":1793747472351,"version":"4.6.1"},"reference-count":55,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:sec id=\"ab-doi220010-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Treatment options for psoriasis (PsO) and psoriatic arthritis (PsA) have evolved significantly throughout the era of biologics. Clinical trials are inadequate to assess the relative long-term efficacy of biologics and are often insufficient regarding safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi220010-5\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the long-term persistence of different biologic classes to treat PsO and PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi220010-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This nationwide cohort study involved the administrative health care database of the French health insurance scheme linked to the hospital discharge database. All adults with PsO and PsA who were new users of biologics (not in the year before the index date) from January 1, 2015, to May 31, 2019, were included and followed up through December 31, 2019. Patients hospitalized for PsA in the PsO cohort and for PsO in the PsA cohort in the year before the index date were excluded. Data were analyzed from June 1 to October 31, 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi220010-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Persistence was defined as the time from biologic therapy initiation to discontinuation and was estimated using the Kaplan-Meier method. Comparison of persistence by biologic class involved using propensity score\u2013weighted Cox proportional hazards regression models and adjustment on specific systemic nonbiologics (time-dependent variables).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi220010-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 16\u202f892 patients with PsO were included in the analysis (mean [SD] age, 48.5\u2009[13.8] years; 9152 men [54.2%] men). Of these, 10\u202f199 patients (60.4%) started therapy with a tumor necrosis factor (TNF) inhibitor; 3982 (23.6%), with an interleukin 12 and interleukin 23 (IL-12\/23) inhibitor; and 2711 (16.0%), with an interleukin 17 (IL-17) inhibitor. An additional 6531 patients with PsA (mean [SD] age, 49.1\u2009[12.8] years; 3565 [54.6%] women) were included; of these, 4974 (76.2%) started therapy with a TNF inhibitor; 803 (12.3%), with an IL-12\/23 inhibitor; and 754 (11.5%), with an IL-17 inhibitor. Overall 3-year persistence rates were 40.9% and 36.2% for PsO and PsA, respectively. After inverse probability of treatment weighting and adjustment, the IL-17 inhibitor was associated with higher persistence compared with the TNF inhibitor for PsO (weighted hazard ratio [HR], 0.78 [95% CI, 0.73-0.83]) and PsA (weighted HR, 0.70 [95% CI, 0.58-0.85]) and compared with the IL-12\/23 inhibitor for PsA (weighted HR, 0.69 [95% CI, 0.55-0.87]). No difference between the IL-17 inhibitor and IL-12\/23 inhibitor for PsO was noted. The IL-12\/23 inhibitor was associated with higher persistence than the TNF inhibitor for PsO (weighted HR, 0.76 [95% CI, 0.72-0.80]), with no difference observed for PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi220010-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The findings of this cohort study suggest that IL-17 inhibitors are associated with higher treatment persistence than the TNF inhibitor for PsO and PsA. Interleukin 17 inhibitors were also associated with higher persistence than the IL-12\/23 inhibitor for PsA, with no difference for PsO. However, the persistence rates of all biologics remained globally low at 3 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.0364","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T11:34:30Z","timestamp":1648035270000},"page":"513","source":"Crossref","is-referenced-by-count":68,"title":["Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database"],"prefix":"10.1001","volume":"158","author":[{"given":"Laura","family":"Pina Vegas","sequence":"first","affiliation":[{"name":"EpiDermE, Universit\u00e9 Paris Est Cr\u00e9teil, Cr\u00e9teil, France"},{"name":"Service de Rhumatologie, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Penso","sequence":"additional","affiliation":[{"name":"EpiDermE, Universit\u00e9 Paris Est Cr\u00e9teil, Cr\u00e9teil, France"},{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products and French National Health Insurance, St Denis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Claudepierre","sequence":"additional","affiliation":[{"name":"EpiDermE, Universit\u00e9 Paris Est Cr\u00e9teil, Cr\u00e9teil, France"},{"name":"Service de Rhumatologie, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[{"name":"EpiDermE, Universit\u00e9 Paris Est Cr\u00e9teil, Cr\u00e9teil, France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Centre d\u2019Investigation Clinique 1430, H\u00f4pital Henri Mondor, Cr\u00e9teil, France"},{"name":"Service de Dermatologie, AP-HP, H\u00f4pital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9997","key":"doi220010r1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis.","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"doi220010r2","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"11","key":"doi220010r3","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1111\/jdv.2018.32.issue-11","article-title":"Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the \u201cOBJECTIFS PEAU\u201d study.","volume":"32","author":"Richard","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi220010r4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies.","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi220010r5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis.","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"doi220010r6","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life.","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"doi220010r7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3899\/jrheum.160180","article-title":"Mapping the effect of psoriatic arthritis using the International Classification of Functioning, Disability and Health.","volume":"44","author":"Gudu","year":"2017","journal-title":"J Rheumatol"},{"issue":"6","key":"doi220010r8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"doi220010r9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi220010r10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis.","volume":"47","author":"Merola","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"doi220010r11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bjd.v184.3","article-title":"Meta-analysis results do not reflect the real safety of biologics in psoriasis.","volume":"184","author":"Afach","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi220010r12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions.","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"issue":"7","key":"doi220010r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jid.2015.171","article-title":"Drug survival studies in dermatology: principles, purposes, and pitfalls.","volume":"135","author":"van den Reek","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"11","key":"doi220010r14","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.3899\/jrheum.140882","article-title":"Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations.","volume":"41","author":"Ogdie","year":"2014","journal-title":"J Rheumatol"},{"issue":"11","key":"doi220010r15","doi-asserted-by":"publisher","DOI":"10.1111\/eci.2018.48.issue-11","article-title":"Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis in real-world settings.","volume":"48","author":"Iannone","year":"2018","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"doi220010r16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13075-021-02417-x","article-title":"Treatment persistence of biologics among patients with psoriatic arthritis.","volume":"23","author":"Haddad","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"doi220010r17","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/rheumatology\/kez427","article-title":"Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.","volume":"59","author":"Brahe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"doi220010r18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bjd.v183.2","article-title":"Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).","volume":"183","author":"Yiu","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi220010r19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/bjd.v184.6","article-title":"Biologic drug survival rates in the era of anti\u2013interleukin-17 antibodies: a time-period\u2013adjusted registry analysis.","volume":"184","author":"Graier","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi220010r20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor a therapy: results from the nationwide Danish DANBIO registry.","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"doi220010r21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","article-title":"French health insurance databases: what interest for medical research?","volume":"36","author":"Moulis","year":"2015","journal-title":"Rev Med Interne"},{"key":"doi220010r22","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the Syst\u00e8me National d\u2019information Interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS) in France.","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"7","key":"doi220010r23","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","article-title":"Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.","volume":"55","author":"Neumann","year":"2012","journal-title":"Diabetologia"},{"issue":"2","key":"doi220010r24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.7326\/M18-1512","article-title":"Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study.","volume":"170","author":"Meyer","year":"2019","journal-title":"Ann Intern Med"},{"issue":"9","key":"doi220010r25","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association between biologics use and risk of serious infection in patients with psoriasis.","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi220010r26","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/rheumatology\/keaa448","article-title":"Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database.","volume":"60","author":"Pina Vegas","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"doi220010r27","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs.","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"doi220010r28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/PPA","article-title":"Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective.","volume":"9","author":"Bolge","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"doi220010r29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997-2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death.","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"issue":"2","key":"doi220010r30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The best use of the Charlson Comorbidity Index with electronic health care database to predict mortality.","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"issue":"2","key":"doi220010r31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/EDE.0000000000000068","article-title":"Commentary: balancing automated procedures for confounding control with background knowledge.","volume":"25","author":"Wyss","year":"2014","journal-title":"Epidemiology"},{"issue":"2","key":"doi220010r32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals.","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"issue":"11","key":"doi220010r33","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi220010r34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/bcp.v87.1","article-title":"Impact of persistence with tumour necrosis factor inhibitors on healthcare resource utilization and costs in chronic inflammatory joint diseases.","volume":"87","author":"Belhassen","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"doi220010r35","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"doi220010r36","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1136\/annrheumdis-2021-220097","article-title":"Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis: data from the EuroSpA collaboration.","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"doi220010r37","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jaad.2016.10.033","article-title":"Biologic drug survival in Israeli psoriasis patients.","volume":"76","author":"Shalom","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi220010r38","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10067-018-3989-2","article-title":"Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis: real-life data from the Biologic Apulian Registry (BIOPURE).","volume":"37","author":"Iannone","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"6","key":"doi220010r39","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1093\/rheumatology\/keaa710","article-title":"Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.","volume":"60","author":"Letarouilly","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"doi220010r40","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/14712598.2020.1761957","article-title":"One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study.","volume":"20","author":"Chimenti","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"doi220010r41","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001519","article-title":"Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.","volume":"7","author":"Ramonda","year":"2021","journal-title":"RMD Open"},{"issue":"4","key":"doi220010r42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.reuma.2019.07.002","article-title":"Secukinumab as biological treatment for psoriatic arthritis in real clinical practice.","volume":"17","author":"Pinto Tasende","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"doi220010r43","doi-asserted-by":"publisher","DOI":"10.1002\/acr.v74.7","article-title":"Real-world 6 and 12-month drug retention, remission and response rates of secukinumab in 2,017 psoriatic arthritis patients in 13 European countries.","author":"Michelsen","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"doi220010r44","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.2016.30.issue-7","article-title":"Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).","volume":"30","author":"Menter","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi220010r45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-020-02380-z","article-title":"Long-term remission and biologic persistence rates: 12-year real-world data.","volume":"23","author":"Murray","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"doi220010r46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.","volume":"148","author":"Garcia-Doval","year":"2012","journal-title":"Arch Dermatol"},{"issue":"10235","key":"doi220010r47","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"doi220010r48","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1093\/rheumatology\/keaa825","article-title":"Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.","volume":"60","author":"Lindstr\u00f6m","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"doi220010r49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjd.2019.180.issue-1","article-title":"Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-na\u00efve patients from the French National Health Insurance database (SNIIRAM).","volume":"180","author":"Sbidian","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi220010r50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.sapharm.2005.12.001","article-title":"Addressing the issue of channeling bias in observational studies with propensity scores analysis.","volume":"2","author":"Lobo","year":"2006","journal-title":"Res Social Adm Pharm"},{"issue":"5","key":"doi220010r51","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor a inhibitor therapy: results from the Danish Nationwide DANBIO Registry.","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"6","key":"doi220010r52","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/14737167.2018.1512408","article-title":"Adherence and resource use among psoriasis patients treated with biologics.","volume":"18","author":"Aleshaki","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"doi220010r53","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"doi220010r54","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.566","article-title":"Evolution of drug survival with biological agents and apremilast between 2012 and 2018 in psoriasis patients from the PsoBioTeq Cohort.","author":"Bettuzzi","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"doi220010r55","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication.","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2790084\/jamadermatology_pina_vegas_2022_oi_220010_1697212101.39195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T11:09:40Z","timestamp":1697627380000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2790084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.0364","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}